Clinical trials: Platelet Disorder
Acute Coronary Syndrome, Coronary Artery Disease
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy.
- Trial name
- NCT03252249
- Testing
- 3 months dual anti-platelet therapy, 12 months dual anti-platelet therapy
- Where
- United Kingdom
- Volunteers
- 5,094 people
- Sponsor
- University of Edinburgh
Crohn Disease, Absorption; Disorder, Protein
Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease
This is a randomized, multicenter, translational, triple-blind, clinical trial in patients with Crohn's disease, who will be prescribed an oral nutritional supplement to control symptoms in the acute phase and to recover in the…
- Conditions
- Crohn Disease, Absorption; Disorder, Protein, Absorption; Disorder, Absorption; Disorder, Fat
- Trial name
- NCT04305535
- Testing
- Peptidic+Probiotic
- Where
- Spain
- Volunteers
- 162 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
L-PRF, Photodynamic Therapy
The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis
Antimicrobial photodynamic therapy (aPDT) is associated with photosensitizing agents which promote the generation of free radicals and singlet oxygen, which are cytotoxic to certain bacteria.
- Conditions
- L-PRF, Photodynamic Therapy, Aggressive Periodontitis
- Trial name
- NCT05043935
- Testing
- L-PRF with antimicrobial photodynamic therapy, antimicrobial photodynamic therapy without L-PRF
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Myeloproliferative Disorders, Leukemia
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting…
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00499668
- Testing
- aprepitant, ondansetron hydrochloride
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatitis C
WEUSKOP5410: Observational Study in ENABLE Clinical Trials
Hepatitis C Virus (HCV) is a leading cause of chronic liver disease (CLD) worldwide. Current mainstay of treatment is combination therapy with pegylated interferon and ribavarin.
- Trial name
- NCT01458080
- Testing
- eltrombopag
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Systemic Inflammatory Response Syndrome, Acute Kidney Injury
Platelets as Regulators of Inflammation in Cardiac Surgery
Platelets are increasingly recognized as a potent and ubiquitously present source of inflammatory activation. Importantly, antiplatelet therapy has been shown to significantly reduce major adverse events such as renal injury in…
- Trial name
- PRICS (NCT02568410)
- Testing
- coronary artery bypass grafting using cardiopulmonary bypass
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Duke University
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
CC-4047 in Treating Patients With Myelofibrosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00669578
- Testing
- CC-4047
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mayo Clinic
Immune Thrombocytopenia, Treatment
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.
- Trial name
- NCT05214391
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Coronary Disease, Platelet Aggregation
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
The purpose of this study is to determine the range of expected PRUTest values in patients in the intended use population receiving dual antiplatelet treatment with aspirin and prasugrel (Effient®), or ticagrelor (Brilinta®).
- Trial name
- NCT04492423
- Testing
- VerifyNow PRUTest
- Volunteers
- 100 people
- Sponsor
- Accriva Diagnostics
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.
- Trial name
- NCT06838962
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenic Purpura, Thyroid Disorders
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment
- Trial name
- NCT07059910
- Testing
- Search for thyroid disorders, Laboratory test, Steroid and eltrombopage
- Volunteers
- 100 people
- Sponsor
- Assiut University
Platelet-Rich Plasma, Acne Vulgaris
Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris
Efficacy and Antimicrobial activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A randomized controlled trial
- Trial name
- NCT03859843
- Testing
- PRP, Chemical peeling (Salycilic acid), Chemical peeling (Jessener's solution)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Thrombocytopenia
The International ITP Registry
Primary immune thrombocytopenia (ITP) is an uncommon disease characterised by a low platelet count, which may cause the patient to have a higher risk or increased duration of bleeding.
- Trial name
- NCT01970189
- Where
- 44 sites in Australia, Colombia and 8 more
- Volunteers
- 500 people
- Sponsor
- South Eastern Sydney Local Health District
Gingival Diseases, Traumatic Injury
Injectable Platelet Rich Fibrin With Collagen Matrix in Treatment of Multiple Gingival Recession.
This study is proposing the use of i-PRF clot as a scaffold for the XCM in order to obtain a novel biomaterial, incorporating active growth factors and collagen matrix in a single framework, based on the potential effect of i-PRF…
- Trial name
- NCT05389059
- Testing
- CAF+CM, I-PRF
- Where
- Iraq
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Baghdad
TMJ Disc Disorder, Treatment
i-PRF for Temporomandibular Joint Disorders
This study will evaluate whether intra-articular injectable platelet-rich fibrin (i-PRF) is more effective than arthrocentesis alone in treating temporomandibular joint (TMJ) disorders.
- Conditions
- TMJ Disc Disorder, Treatment, Arthrocentesis
- Trial name
- NCT07188974
- Testing
- Arthrocentesis (lavage only), Arthrocentesis + Injectable Platelet-Rich Fibrin (i-PRF)
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eskisehir Osmangazi University
Hemolytic-Uremic Syndrome
Efficacy of INM004 in Children With STEC-HUS
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
- Trial name
- NCT06389474
- Testing
- INM004
- Where
- 52 sites in Argentina, Belgium and 7 more
- Volunteers
- 220 people
- Sponsor
- Inmunova S.A.
Chronic Myeloproliferative Disorders, Kidney Cancer
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00295997
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)